November 1, 2007

Hib Vaccine Shortage Likely

Merck & Co., Inc. is reporting manufacturing problems that will likely result in a shortage of its Haemophilus influenzae type B (Hib) vaccine, PedvaxHIB (PRP-OMP), according to the Centers for Disease Control and Prevention (CDC). 

CDC says it will dip into its vaccine stockpile to make up limited amounts of the vaccine, and Sanofi Pasteur says it is working to provide additional supplies of its ActHib (PRP-T) vaccine. CDC estimates providers will need to use ActHib for about half of their Hib vaccine needs. 

The CDC announcement has instructions for providers whose patients have already started a vaccine series with Merck’s PRP-OMP vaccine and must complete it with Sanofi Pasteur’s PRP-T vaccine.

Merck expects PedvaxHIB to be available sometime in the first quarter of 2008, depending on when its manufacturing issue is resolved.

For more information on vaccine shortages, see

< Previous Article | Next Article >

ACIP Recommends Meningococcal Vaccine for High-Risk Two-Year-Olds
EIN Reports Cases of Severe Neonatal Enteroviral Disease
Hib Vaccine Shortage Likely
Hot Topics in Infectious Diseases 2007
IDSA Publishes Updated Guidelines on Sporotrichosis
In the IDSA Journals
Low Rates of Flu Vaccination Underscore Need for Vigilance
New CA-MRSA Evaluation and Treatment Flyer Available
CDC Creates Database of State Immunization Laws
New Compilation of Latest HIV Research Available
Stay Informed about Daily ID News
Updated IDSA/SHEA Infection Control Fellows Course Available
Call for Public Comment: HIV/AIDS Performance Measures
Support Builds for STAAR Act
Keep Up with Drug Approvals, Recalls, Adverse Events
Vaccine-derived Polio Outbreak in Nigeria
Welcome, New IDSA Members!
Search Back Issues
Forward this Issue
Print-Friendly Version

Copyright IDSA 2008 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209

Home Page Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA